Published in J Cardiovasc Pharmacol on June 01, 1996
Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest (1997) 4.92
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest (2000) 4.36
VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest (1999) 2.08
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Vascular endothelial growth factors and vascular permeability. Cardiovasc Res (2010) 1.89
Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest (1997) 1.43
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer (2008) 1.30
Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? Thorax (2006) 1.26
Utilization of the delay phenomenon improves blood flow and reduces collagen deposition in esophagogastric anastomoses. Ann Surg (2005) 1.14
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol (2010) 1.11
Quantitative high-throughput profiling of snake venom gland transcriptomes and proteomes (Ovophis okinavensis and Protobothrops flavoviridis). BMC Genomics (2013) 1.06
Nutritional modulation of age-related macular degeneration. Mol Aspects Med (2012) 0.97
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist (2011) 0.95
Delivery of VEGF using collagen-coated polycaprolactone scaffolds stimulates angiogenesis. J Biomed Mater Res A (2011) 0.92
Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol (2013) 0.90
Vascular endothelium growth factor, surgical delay, and skin flap survival. Ann Surg (2004) 0.89
Gene delivery technologies for cardiac applications. Gene Ther (2012) 0.87
The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci (2012) 0.87
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer (2009) 0.86
Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, rapamycin-dependent gene switch. Hum Gene Ther Methods (2013) 0.83
The Key Role of the Blood Supply to Bone. Bone Res (2013) 0.83
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br J Pharmacol (2014) 0.82
[(Side) effects of VEGF inhibition]. Ophthalmologe (2006) 0.82
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol (2014) 0.81
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist (2010) 0.81
Individualized therapy of HHT driven by network analysis of metabolomic profiles. BMC Syst Biol (2011) 0.81
Expression of growth factors during the healing process of alveolar ridge augmentation procedures using autogenous bone grafts in combination with GTR and an anorganic bovine bone substitute: an immunohistochemical study in the sheep. Clin Oral Investig (2013) 0.81
Pulmonary vascular dysfunction in ARDS. Ann Intensive Care (2014) 0.80
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI. NMR Biomed (2012) 0.80
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol (2015) 0.79
Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol (2008) 0.79
Local over-expression of VEGF-DΔNΔC in the uterine arteries of pregnant sheep results in long-term changes in uterine artery contractility and angiogenesis. PLoS One (2014) 0.78
Circulating vascular endothelial growth factor and nitric oxide in patients with liver cirrhosis: A possible association with liver function impairment. Indian J Clin Biochem (2009) 0.75
Sunitinib side effects as surrogate biomarkers of efficacy. Can Urol Assoc J (2017) 0.75
Microglia preconditioned by oxygen-glucose deprivation promote functional recovery in ischemic rats. Sci Rep (2017) 0.75
Improvement of a long random skin flap survival by application of vascular endothelial growth factor in various ways of local administration in a rat model. Indian J Plast Surg (2012) 0.75
Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs. J Vet Intern Med (2016) 0.75
Pulp bleeding color is an indicator of clinical and histohematologic status of primary teeth. Clin Oral Investig (2017) 0.75
Integrating functional genomic information into the Saccharomyces genome database. Nucleic Acids Res (2000) 18.52
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Stochastic kinetic analysis of developmental pathway bifurcation in phage lambda-infected Escherichia coli cells. Genetics (1998) 12.21
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut (2009) 8.98
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
In vitro synthesis of DNA complementary to purified rabbit globin mRNA (RNA-dependent DNA polymerase-reticulocyte-hemoglobin-density gradient centrifugation-oligo(dT) primer). Proc Natl Acad Sci U S A (1972) 7.89
The Stanford Microarray Database. Nucleic Acids Res (2001) 7.77
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Genome-wide expression profiling in Escherichia coli K-12. Nucleic Acids Res (1999) 7.20
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Fiber orientation in the canine left ventricle during diastole and systole. Circ Res (1969) 7.01
The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA (1997) 6.32
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet (1993) 5.97
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A (1995) 5.92
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A (1991) 5.60
A precursor of globin messenger RNA. J Mol Biol (1976) 5.34
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Phenological changes reflect climate change in Wisconsin. Proc Natl Acad Sci U S A (1999) 4.99
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell (1997) 4.67
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
Expression of active human factor VIII from recombinant DNA clones. Nature (1984) 4.36
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med (1998) 4.16
Globin messenger-RNA induction during erythroid differentiation of cultured leukemia cells. Proc Natl Acad Sci U S A (1972) 4.02
Poly(A) shortening and degradation of the 3' A+U-rich sequences of human c-myc mRNA in a cell-free system. Mol Cell Biol (1988) 3.96
Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia. Cell (1981) 3.80
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem (1998) 3.80
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 3.76
Towards functional characterisation of the members of the R2R3-MYB gene family from Arabidopsis thaliana. Plant J (1998) 3.75
Separation of murine cellular and murine leukaemia virus DNA polymerases. Nat New Biol (1971) 3.71
The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro. Mol Cell Biol (1989) 3.69
Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis (1995) 3.66
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol (1990) 3.57
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Aortic stenosis. Circulation (1968) 3.49
Obliquity-paced Pliocene West Antarctic ice sheet oscillations. Nature (2009) 3.42
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Cyclosporine-associated chronic nephropathy. N Engl J Med (1984) 3.39
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron (1995) 3.37
Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation (1996) 3.34
Structure of human factor VIII. Nature (1984) 3.29
Mean velocity of fiber shortening. A simplified measure of left ventricular myocardial contractility. Circulation (1971) 3.19
A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell (2001) 3.13
Long term acid suppressing treatment in general practice. BMJ (1994) 3.11
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Selective suppression of the magnocellular visual pathway during saccadic eye movements. Nature (1994) 3.00
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem (1997) 2.95
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. Genes Dev (1992) 2.90
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Poly(A), poly(A) binding protein and the regulation of mRNA stability. Trends Biochem Sci (1989) 2.78
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A (1998) 2.76
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol (1982) 2.73
Saccharomyces Genome Database provides tools to survey gene expression and functional analysis data. Nucleic Acids Res (2001) 2.71
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res (1999) 2.70
Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell (1999) 2.68
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Immunological relationships of reverse transcriptases from ribonucleic acid tumor viruses. J Virol (1972) 2.65
H4 histone messenger RNA decay in cell-free extracts initiates at or near the 3' terminus and proceeds 3' to 5'. J Mol Biol (1986) 2.63
Regulation of mRNA turnover in eukaryotic cells. Crit Rev Eukaryot Gene Expr (1991) 2.62
Regional myocardial function during acute coronary artery occlusion and its modification by pharmacologic agents in the dog. Circ Res (1974) 2.57
A review and meta-analysis of the patient factors associated with psychiatric in-patient aggression. Acta Psychiatr Scand (2013) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med (1998) 2.43
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. Am J Cardiol (1988) 2.42
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
Estimation of VO2max from a one-mile track walk, gender, age, and body weight. Med Sci Sports Exerc (1987) 2.34
Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component. Mol Cell Biol (1989) 2.33
Skeletal repair by in situ formation of the mineral phase of bone. Science (1995) 2.33
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Globin gene expression in cultured erythroleukemic cells. J Mol Biol (1974) 2.28
Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem (1995) 2.27
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27